Picture loading failed.

Pre-Made Nurulimab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Nurulimab (also known as BCD 145) is a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) for the treatment of cancer

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-382-1mg 1mg 3090
GMP-Bios-ab-382-10mg 10mg Inquiry
GMP-Bios-ab-382-100mg 100mg Inquiry
GMP-Bios-ab-382-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Nurulimab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
INN Name Nurulimab
TargetCTLA-4
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI Structure5xj3:AB/5tru:HL/6jc2:HL
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesBiocad
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedMalignant melanoma
Development Techna